WO2008030134A1 - Method for producing microcapsulated medicinal substances in the form of micronised water-dispersible powders and pastes - Google Patents
Method for producing microcapsulated medicinal substances in the form of micronised water-dispersible powders and pastes Download PDFInfo
- Publication number
- WO2008030134A1 WO2008030134A1 PCT/RU2006/000493 RU2006000493W WO2008030134A1 WO 2008030134 A1 WO2008030134 A1 WO 2008030134A1 RU 2006000493 W RU2006000493 W RU 2006000493W WO 2008030134 A1 WO2008030134 A1 WO 2008030134A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- deposition surface
- deposition
- condensation
- organic
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
Definitions
- the invention relates to the field of production of micronized water-dispersed organic drug substances and can be used in the manufacture of dosage forms and in cosmetics.
- the disadvantage of this method is the impossibility of obtaining water-dispersible drug substances and the strong dependence of the particle sizes of drugs on the temperature on the condensation surface, since in real conditions the temperature of the condensation surface in its various places is heterogeneous, since it is lower at the point of contact with the refrigerant, and as the distance from the point of contact increases, and due to the difference in the conditions of condensation (temperature) in one technological cycle, the particle size of the obtained pulses varies from 0.008 to 0.018 ⁇ m, which reduces the efficiency of the use of the obtained drug, since one of the factors for the assimilation of powdered drugs by the body is its particle size, which determines the rate of concentration of the drug in the body.
- the disadvantages of the above-mentioned method are that the particles of the obtained powders of medicinal organic substances with a size of 0.008-0.010 ⁇ m are in a fused state and additional efforts are required to transfer them to a free-dispersed state.
- the sizes of the fused particles are in the range from 1 to 30 microns, and the conditions for the production of powders in the specified method do not allow to achieve a narrower particle size distribution.
- the resulting micronized drug substances are not water dispersible and do not form aggregatively stable suspensions and colloidal solutions,
- the objective of the proposed invention is to reduce the complexity and cost of a one-stage production of microencapsulated drug substances in the form of micronized water-dispersible and aggregatively stable powders and pastes of soluble and water-insoluble organic substances with a narrow range of particle sizes when using low vacuum in the range of average particle sizes of 0.5 - 5.0 microns without any additional force.
- the evaporation rates of organic drug substances and auxiliary surfactants can exceed their deposition rates by 1.2 - 2.5 times.
- the invention consists in the following: the starting organic drug substance and auxiliary surfactant are simultaneously evaporated in a gaseous medium having a vacuum of 1.0 - 10 * Topp. After that, the obtained pairs of medicinal substances and auxiliary surfactants co-condense, respectively, at speeds of 3 • 1O 1Z -10 17 molecules / sec • cm 2 and 10 14 - 5 - 10 1?
- the use of simultaneous evaporation of a medicinal organic substance and auxiliary surfactant in a gas medium with a low degree of discharge facilitates the implementation of the used technological processes and reduces capital costs.
- the upper limit of the temperature of the deposition surface indicated in the claims is due to the fact that with an increase in the temperature of the deposition surface above 5O 0 C, the proportion of the drug substance and excipient deposited on the surface decreases.
- the allowable lower and upper limits of the deposition rate indicated in the claims determine, respectively, with a decrease in the deposition rate, an increase in the average size of the resulting particles, and when With an increase in the deposition rate, the temperature gradient sharply increases over the layer of the deposited substance, which leads to an increase in the heterogeneity of the obtained powders, both in particle size and in internal structure.
- FIG. 1 shows a photograph of microencapsulated particles of carvedilol powder dispersed in water, illustrating Example 1;
- figure 2 is a diagram of the size distribution of microencapsulated particles of carvedilol powder dispersed in water, explaining example 1;
- Fig. 3 is a photograph of microencapsulated particles of carvedilol powder dispersed in water, illustrating Example 2;
- Fig. 4 is a particle size distribution diagram of microencapsulated particles of carvedilol powder dispersed in water, illustrating Example 2; in FIG. 5 - IR spectra of the original carvedilol, Tween 80 and suspensions of examples 1 and 2 after evaporation of water.
- IR spectrum 1 Tween 80
- IR spectrum 2 Carvedilol
- IR spectrum 3 suspensions of Example 1
- IR spectrum 4 suspension of Example 2 3 minutes after preparation
- IR spectrum 5 suspensions of Example 2 50 minutes after receipt
- FIG. 6 is a photograph of microencapsulated particles of phenazepam powder dispersed in water, illustrating Example 3
- 7 is a diagram of the size distribution of microencapsulated particles of phenazepam powder dispersed in water, illustrating Example 3
- FIG 8 is a photograph of microencapsulated particles of phenazepam powder dispersed in water, illustrating Example 4;
- figure 9 is a diagram of the size distribution of microencapsulated particles of water-dispersed phenazepam powder, illustrating example 4;
- Example 15 - IR spectra of the initial monoglyceride, captopril and suspension according to example 7 after evaporation of water IR spectrum 1 - monoglyceride, IR spectrum 2 - captopril, IR spectrum 3 - captopril suspension 3 minutes after receipt, and IR spectrum 4 - Captopril suspension after settling (settling) for 3 hours).
- Example 1 The powder of the original carvedilol (practically insoluble in water) with an average particle size of 70 - 110 ⁇ m and Tween 80 were placed in separate evaporators placed in the reactor.
- the gas medium is pumped out of the reactor until it reaches a vacuum level of 6 - 10 ⁇ Torr and the deposition surface is cooled to - 4O 0 C, setting it first at an angle of 15 ° to the bisector of the angle between the vectors of the condensation rates of carvedilol and Tween 80 equal to 20 °.
- heating of the surfaces of the evaporators is included.
- the co-condensation process is completed in the reactor, it is opened after casting pressure in it to atmospheric and heating the deposition surface to room temperature. Then, microencapsulated fine powder is collected from the deposition surface, which forms a suspension with an average particle size of 0.9 microns under stirring with distilled water.
- the IR spectrum of the dehydrated suspension indicates the presence of carvedilol and tween 80 in the dry residue, which is confirmed by thin layer chromatography.
- Example 2 The starting carvedilol powder (practically insoluble in water) with an average particle size of 70-110 microns and Tween 80 were placed in separate evaporators placed in the reactor. After that, the gas medium is pumped out of the reactor until it reaches a vacuum level of 10 " Torr and the deposition surface is cooled to O 0 C, setting it first at an angle of 18 ° to the bisector of the angle between the vectors of the condensation rates of carvedilol and Tween 80 equal to 25 °.
- reactor above the gas medium degree of vacuum and a predetermined deposition surface temperature include heating surface of the evaporator components in the ratio 1:.
- the powder of the initial phenazepam (insoluble in water) with an average particle size of 50 - 80 ⁇ m and Tween 80 were placed in separate evaporators placed in the reactor. After that, the gas medium was pumped out of the reactor until it reached a discharge level of 0.5 Torr and its preliminary deposition surface was set at an angle of 10 ° to the angle bisector of the angle between the vectors of the condensation rates of phenazepam and Tween 80 equal to 22 °. Upon reaching the aforementioned degree of rarefaction of the gaseous medium in the reactor and the temperature of the deposition surface equal to 25 0 C include heating the surfaces of the evaporators. The components in a ratio of 1: 0.3 condense on the deposition surface at a rate of 4 • 10 " molecules / sec • cm" for phenazepam and 1.2 •
- Phenazepam starting powder (insoluble in water) with an average particle size of 50 - 80 ⁇ m and Cremophor were placed in separate evaporators placed in the reactor, after which the gaseous medium was pumped out from the reactor until it reached a vacuum of 0.5 Torr and cooled the deposition surface is up to - 60 0 C, having previously set it at an angle of 16 ° to the bisector of the angle between the vectors of the condensation rates of phenazepam and Cremophor equal to 20 °.
- rarefaction of the gaseous medium and the specified temperature of the deposition surface include heating the surfaces of the evaporators.
- the deposition surface is heated to room temperature.
- microencapsulated fine powder is collected from the deposition surface, which, when mixed with distilled water, forms a suspension with an average particle size of 1.4 ⁇ m according to optical microscopy.
- the IR spectrum of the dried, dried suspension indicates the presence of phenazepam and Cremophor in the dry residue, which is confirmed by thin-layer chromatography.
- Example 5 The powder of the initial phenazepam (insoluble in water) with an average particle size of 50-80 ⁇ m and Cremophor were placed in separate evaporators placed in the reactor. After that, the gas medium was pumped out of the reactor until it reached a degree of vacuum of 2.5Topp and the deposition surface was heated to 4O 0 C 1 by setting it first at an angle of 16 ° to the angle bisector between the vectors of the condensation rates of phenazepam and Cremophor equal to 20 °. Upon reaching the above-mentioned degree of rarefaction of the gaseous medium in the reactor and the desired temperature of the deposition surface, heating of the surfaces of the evaporators is included.
- Example 6 The powder of the initial phenazepam (insoluble in water) with an average particle size of 70 - 110 ⁇ m and stearic acid were placed in separate evaporators placed in the reactor. Then the gaseous medium is pumped out of the reactor until it reaches a vacuum level of 10 " Torr and the deposition surface is cooled to - 7O 0 C, setting it first at an angle of 18 ° to the angle bisector between the vectors of the condensation rates of phenazepam and stearic acid equal to 25 °.
- heating of the surfaces of the evaporators is included.
- At the end of the co-condensation process in the reactor it is opened after the pressure in it is brought to atmospheric pressure and the deposition surface is heated to room temperature.
- microencapsulated fine powder is collected from the deposition surface, which, when mixed with 0.1 M NaHCO 3 in distilled water, forms a suspension with an average particle size of 1.3 and 4.4 ⁇ m according to optical microscopy.
- the IR spectrum of the dehydrated suspension indicates the presence of phenazepam and sodium stearate in the dry residue, which is confirmed by thin layer chromatography.
- Example 7 The starting captopril powder (soluble in water) with an average particle size of 65 - 90 microns and the monoglyceride were placed in separate evaporators placed in the reactor.
- the gaseous medium is pumped out of the reactor until it reaches a vacuum level of 2.5 • 10 "z Torr and the deposition surface is cooled to - 1O 0 C 1 by setting it first at an angle of 15 ° to the bisector of the angle between the captopril and mo- noglyceride equal to 24 °.
- heating of the surfaces of the evaporators is included.
- the components in the ratio 1 0.9 condense on the deposition surface at a rate of 3 * 10 ⁇ molecule / s - cm * for captopril and 2.7 - 10 ⁇ mol / s • cm * for monoglyceride.
- Example 8 The powder of the original captopril (insoluble in water) with an average particle size of 65 - 90 microns and tristearin are placed in separate evaporators placed in the reactor. After that, the gas medium is pumped out of the reactor until it reaches a vacuum level of 7 - 10 " * Torr and the deposition surface is cooled to O 0 C, having previously been set at an angle of 16 ° to the bisector of the angle between the vectors of the condensation rates of captopril and tristearin equal to 20 °. Upon reaching the aforementioned degree of rarefaction of the gaseous medium and a predetermined temperature in the reactor, the deposition surface includes heating the surfaces of the evaporators.
- a finely dispersed powder is collected from the deposition surface, forming a suspension with captopril particles microencapsulated in tristearin when mixed with distilled water.
- the encapsulated captopril in an aqueous solution is not more than 0.01 of the dissolution rate of the initial captopril.
- the IR spectrum of the dehydrated aqueous extract taken 3 hours after placing the sample in water indicates the transition of captopril microencapsulated in tristearin in an amount of not more than 3-5 %, which is confirmed by thin layer chromatography.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2006131665/15A RU2321392C1 (en) | 2006-09-05 | 2006-09-05 | Method for producing microcapsulated drugs as micronized water-dispersed powders and/or pastes |
RU2006131665 | 2006-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008030134A1 true WO2008030134A1 (en) | 2008-03-13 |
Family
ID=39157477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2006/000493 WO2008030134A1 (en) | 2006-09-05 | 2006-09-25 | Method for producing microcapsulated medicinal substances in the form of micronised water-dispersible powders and pastes |
Country Status (2)
Country | Link |
---|---|
RU (1) | RU2321392C1 (en) |
WO (1) | WO2008030134A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0209403B1 (en) * | 1985-07-15 | 1991-10-23 | Research Development Corporation of Japan | Process for preparing ultrafine particles of organic compounds |
US5384133A (en) * | 1986-08-11 | 1995-01-24 | Innovata Biomed Limited | Pharmaceutical formulations comprising microcapsules |
RU2073507C1 (en) * | 1993-04-15 | 1997-02-20 | Химический факультет МГУ им.М.В.Ломоносова | Method for powdery drug preparation |
RU2195264C1 (en) * | 2001-07-05 | 2002-12-27 | Химический факультет МГУ им. М.В.Ломоносова | Method of medicinal preparation powder preparing |
-
2006
- 2006-09-05 RU RU2006131665/15A patent/RU2321392C1/en not_active IP Right Cessation
- 2006-09-25 WO PCT/RU2006/000493 patent/WO2008030134A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0209403B1 (en) * | 1985-07-15 | 1991-10-23 | Research Development Corporation of Japan | Process for preparing ultrafine particles of organic compounds |
US5384133A (en) * | 1986-08-11 | 1995-01-24 | Innovata Biomed Limited | Pharmaceutical formulations comprising microcapsules |
RU2073507C1 (en) * | 1993-04-15 | 1997-02-20 | Химический факультет МГУ им.М.В.Ломоносова | Method for powdery drug preparation |
RU2195264C1 (en) * | 2001-07-05 | 2002-12-27 | Химический факультет МГУ им. М.В.Ломоносова | Method of medicinal preparation powder preparing |
Also Published As
Publication number | Publication date |
---|---|
RU2321392C1 (en) | 2008-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU680727B2 (en) | Process for drying a material from solution | |
Shen et al. | Stabilized amorphous state of ibuprofen by co‐spray drying with mesoporous SBA‐15 to enhance dissolution properties | |
CN101123989B (en) | A process for the preparation of a piroxicam: betacyclodextrin inclusion compound | |
KR20130066695A (en) | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery | |
CN108463213B (en) | Preparation of inhalable zafirlukast particles | |
Barman et al. | Development of highly stable nifedipine solid–lipid nanoparticles | |
Chen et al. | Rapid dissolution of high‐potency danazol particles produced by evaporative precipitation into aqueous solution | |
Leng et al. | Formulating inhalable dry powders using two-fluid and three-fluid nozzle spray drying | |
Wu et al. | Sub-micrometric polymer particles formation by a supercritical assisted-atomization process | |
WO2008030134A1 (en) | Method for producing microcapsulated medicinal substances in the form of micronised water-dispersible powders and pastes | |
Mendiratta et al. | Lansoprazole solid dispersion using a novel amphiphillic polymer Soluplus® | |
JP6797176B2 (en) | Method for producing fine particles of poly (lactic acid-co-glycolic acid) copolymer | |
RU2391976C2 (en) | Pharmaceutic composition in form of microencapsulated polycomponent particles of n-carbamoil-methyl-4-phenyl-2-pyrrolidon and neutral organic small-molecular adjuvant and method of its microcapsulation | |
RU2301058C1 (en) | Method for micronization of organic medicinal substance | |
US8207236B2 (en) | Method for the production of porous particles | |
RU2465892C1 (en) | Method of obtaining highly dispersed meloxicame | |
RU2347565C1 (en) | Pharmaceutical water-soluble formulation from active principle in form of n-carbamoyl-methyl-4-phenyl-2-pyrrolidone and at least one auxiliary neutral organic low-molecular component and methods of its preparation | |
Bhosale et al. | Preparation of amorphous carvedilol polymeric microparticles for improvement of physicochemical properties | |
RU2195264C1 (en) | Method of medicinal preparation powder preparing | |
RU2073507C1 (en) | Method for powdery drug preparation | |
US9511341B2 (en) | Method for preparing acetazolamide sodium powder | |
RU2331409C1 (en) | Method for production of micronised powder of incapsulated organic drug substance with slow dissolution rate | |
JP2011514897A (en) | Method for preparing highly concentrated aqueous micellar solution | |
RU2423968C1 (en) | Method of obtaining micronised powder of organic medicinal substance with increased rate of solubility and bioavailability | |
Choi et al. | Development of coated nifedipine dry elixir as a long acting oral delivery with bioavailability enhancement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06849587 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06849587 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A, 20.07.09) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06849587 Country of ref document: EP Kind code of ref document: A1 |